Outcomes of Endovascular Treatment in Patients with Superficial Femoral Artery In-Stent Restenosis

Thabet, Bahgat Abdelhamid; Ahmed, Mahmoud Ismael; Ahmed, Mohamed Ibrahim; Mahrous, Mark Malak

doi:10.21608/ejhm.2023.287336

Outcomes of Endovascular Treatment in Patients with Superficial Femoral Artery In-Stent Restenosis

Document Type : Original Article

Authors

10.21608/ejhm.2023.287336

Abstract

Background: The femoropopliteal artery lesions classed as trans-Atlantic inter-society consensus (TASC) A-C lesions and some TASC D cases should be treated with endovascular therapy, according to current recommendations (Level C, Class I, recommendations based on expert opinion and retrospective studies)
Aim: This study aimed to evaluate the effectiveness and safety of endovascular balloon angioplasty in cases of superficial femoral artery stenosis.
Patients and Methods: This study was presented to the faculty of medicine's department of vascular surgery at Assiut University Hospital between October 2019 and October 2021. It is a prospective hospital-based study for patients with superficial femoral artery in-stent restenosis.
Results: The primary patency rate at 12 months was 82.6%, demonstrating that none of the 23 patients who received effective endovascular therapy experienced any loss of function or passed away during the observation period.
Conclusion: Endovascular treatment is a safe and effective way for treating chronic lower limb ischemia caused by SFA-ISR. Both DCB and traditional balloon angioplasty are associated with low post-procedural morbidity and death. It is an excellent surgical replacement with a high rate of technical success. Drug-coated balloon angioplasty is a helpful operation with a significant decrease in recurring stenosis and repeat angioplasty for up to a year because of the anti-proliferative effects of paclitaxel.

Keywords